De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial

The Lancet Haematology

Volumn 4, Issue 7, 2017, Pages e310-e316

  Clark, Richard E ^a   Polydoros, Fotios ^b   Apperley, Jane F ^c   Milojkovic, Dragana ^c   Pocock, Christopher ^d   Smith, Graeme ^e   Byrne, Jenny L ^f   de Lavallade, Hugues ^g   O'Brien, Stephen G ^h   Coffey, Tony ^b   Foroni, Letizia ^c   Copland, Mhairi ⁱ  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g KING S COLLEGE HOSPITAL   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; FATALITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; PHASE 2 CLINICAL TRIAL; TREATMENT WITHDRAWAL;

AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 85019664429     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(17)30066-2     Document Type: Article

References (20)

1. Bower, H, Björkholm, M, Dickman, PW, Höglund, M, Lambert, PC, Andersson, TM, Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34 (2016), 2851–2857.
2. Steegmann, JL, Baccarani, M, Breccia, M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 30 (2016), 1648–1671.
3. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121 (2013), 4439–4442.
4. Hughes, TP, Ross, DM, Moving treatment-free remission into mainstream clinical practice in CML. Blood 128 (2016), 17–23.
5. Saußele, S, Richter, J, Hochhaus, A, Mahon, FX, The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 30 (2016), 1638–1647.
6. Mahon, FX, Réa, D, Guilhot, J, et al., Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncology 11 (2010), 1029–1035.
7. Etienne, G, Guilhot, J, Rea, D, et al. Long-term follow-up of the French Stop Imatinib study (STIM1) in patients with chronic myeloid leukemia. J Clin Oncol 35 (2017), 298–305.
8. Ross, DM, Branford, S, Seymour, JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122 (2013), 515–522.
9. Rousselot, P, Charbonnier, A, Cony-Makhoul, P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32 (2014), 424–430.
10. Lee, SE, Choi, SY, Song, HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 101 (2016), 717–723.
11. Richter J, Mahon FX, Guilhot J, et al. Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial. European Haematology Association 21st Annual Meeting; Copenhagen, Denmark; June 10, 2016. S145.
12. Kuwabara, A, Babb, A, Ibrahim, A, et al. Poor outcome after reintroduction of imatinib in patients with CML who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood 116 (2010), 1014–1016.
13. Brooks, R, EuroQol: the current state of play. Health Policy 37 (1996), 53–72.
14. Bacik, J, Mazumdar, M, Murphy, BA, et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual Life Res 13 (2004), 137–154.
15. Russo, D, Martinelli, G, Malagola, M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood 121 (2013), 5138–5144.
16. Richter, J, Söderlund, S, Lübking, A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?. J Clin Oncol 32 (2014), 2821–2823.
17. Hahn, EA, Glendenning, GA, Sorensen, MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21 (2003), 2138–2146.
18. Aziz, Z, Iqbal, J, Aaqib, M, Akram, M, Saeed, A, Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52 (2011), 1017–1023.
19. Williams, LA, Garcia Gonzalez, AG, Ault, P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 122 (2013), 641–647.
20. Efficace, F, Baccarani, M, Breccia, M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23 (2014), 825–836.